Farmacoterapias paliativas para la disnea de la fibrosis quística
Información
- DOI:
- https://doi.org/10.1002/14651858.CD011855.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 10 agosto 2017see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Fibrosis quística y enfermedades genéticas
- Copyright:
-
- Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
| Roles and responsibilities | |
| TASK | WHO WILL UNDERTAKE THE TASK? |
| Protocol stage: draft the protocol | NJ, MS, AA, KKT |
| Review stage: select which trials to include (2 + 1 arbiter) | NJ, KKT, MS |
| Review stage: extract data from trials (2 people) | NJ, AA |
| Review stage: enter data into RevMan | NJ |
| Review stage: carry out the analysis | NJ, MS, AA, KKT |
| Review stage: interpret the analysis | NJ, MS, AA, KKT |
| Review stage: draft the final review | NJ, MS, AA, KKT |
| Update stage: update the review | NJ, MS, AA, KKT |
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.
Declarations of interest
All authors: none known.
Acknowledgements
ICMR Advanced Centre for Evidence‐based Child Health, PGIMER, Chandigarh, India.
The Cochrane Cystic Fibrosis and Genetic Disorders Review Group and Nikki Jahnke (Managing Editor) for helping with and co‐ordinating this review.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 Apr 28 | Palliative drug treatments for breathlessness in cystic fibrosis | Review | Nishant Jaiswal, Meenu Singh, Amit Agarwal, Anil Chauhan, Nikita Jaiswal | |
| 2017 Aug 10 | Palliative drug treatments for breathlessness in cystic fibrosis | Review | Nishant Jaiswal, Meenu Singh, Amit Agarwal, Kiran K Thumburu | |
| 2015 Sep 02 | Drug treatments for breathlessness in end‐stage cystic fibrosis | Protocol | Nishant Jaiswal, Meenu Singh, Amit Agarwal, Kiran K Thumburu | |
Differences between protocol and review
The authors have removed the term 'end‐stage' from the title of the review. While this alters the scope of the review which was originally focused on end‐stage disease, we are aware that treatments previously seen as palliative are now used earlier rather than waiting until end of life and can be used simultaneously with therapies designed to prolong life.
It was also clinically relevant to include comparisons of any pharmacological interventions to placebo, hence this possible comparison was also added as a post hoc change.
Following statistical advice, it was decided to present any results for dichotomous outcomes using the risk ratio rather than the odds ratio.
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Humans;
PICO
Study flow diagram.
